Figure 1. Micrographs of spinal cord motoneurons showing SOD1-immunoreactive inclusions.
Image credit: Forsberg, et. al. 2010 under CC BY license

Funding Opportunities

To submit any new grant opportunities for this list, please email [email protected]. List the sponsor name, amount, due date, and contact information.

 


 

Current Funding Opportunities:


NEW! Rare Innovation Challenge
Sponsor: Sanofi Genzyme
Description: Sanofi Genzyme invites you to partner with us in reducing the time to diagnosis for rare diseases. We are looking for innovative digital health, medtech or technology companies (startups or otherwise) that can apply their technologies to the challenges that keep patients from receiving accurate, timely diagnoses of rare diseases.  
Deadline: Application due by July 27, 2018.



NEW! MDA Venture Philanthropy Program
Sponsor: Muscular Dystrophy Association
Description: MDA’s MVP program is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases. The diseases funded include ALS. MVP funds projects from proof-of-principle studies through phase 2 trials. The maximum award is  $1M USD for preclinical studies, $3M USD for early clinical studies and $500,000 USD for R&D.
Deadline: Letter of Intent due by September 1, 2018.



NEW! Tools to Target, Identify and Characterize Non-Neuronal Cells in the Brain.
Sponsor: NIH BRAIN Initiative
Description: The purpose of this Funding Opportunity Announcement [FOA] submitted through the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to stimulate the development and validation of novel tools and analytical methods to target, identify and characterize non-neuronal cells in the brain.
Deadline: Letter of Intent due by September 4, 2018.



NEW! Basic Research Pilot Grants
Sponsor: AFTD
Description: AFTD Pilot Grants provide seed funding for innovative research projects in the preliminary stages of development with the potential to increase our understanding of frontotemporal degeneration (FTD) across the full spectrum of FTD disorders: behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, corticobasal syndrome, and FTD-ALS. The award is $60,000 USD for 1 year. New or early-stage investigators in the process of establishing an independent research program across the globe are invited to apply. Applications are welcome from biotech start-ups.
Deadline: Application due by September 7, 2018.



NEW! Clinical Research Pilot Grants
Sponsor: AFTD
Description: Clinical Research Pilot Grants support projects seeking to answer questions relevant to FTD clinical practice, evaluate novel clinical trial designs, or develop innovative diagnostic and prognostic measures (e.g., rating scales). Approaches that employ novel technologies, such as remote monitoring or wearable devices, are especially encouraged. Examples of research topics suitable for Clinical Research Pilot Grants include, but are not limited to: early-stage drug discovery for disease-modifying or symptomatic treatment of FTD, genetics, genomics, or epigenetics of FTD, algorithms and machine learning approaches to brain image analysis, neural network approaches to understanding the neural basis of FTD symptoms, development and validation of FTD-specific outcome measures, simulation studies of innovative clinical trial designs. The award is $60,000 USD for 1 year. New or early-stage investigators in the process of establishing an independent research program across the globe are invited to apply. Applications are also welcome from biotech start-ups.
Deadline: Application due by September 7, 2018.



NEW! Rare Diseases Clinical Research Consortia
Sponsor: NIH
Description: The purpose of this Funding Opportunity Announcement (FOA) is to invite new and renewal applications for the Rare Diseases Clinical Research Consortia (RDCRC) that comprise the Rare Diseases Clinical Research Network (RDCRN).  The RDCRCs are intended to advance the diagnosis, management, and treatment of rare diseases with a focus on clinical trial readiness.  Each RDCRC will promote highly collaborative, multi-site, patient-centric, translational and clinical research with the intent of addressing unmet clinical trial readiness needs. This includes biomarkers, outcome assessment measures and studies that inform inclusion and exclusion criteria, timing of the intervention and sample size.
Deadline: Letter of Intent due by September 9, 2018.



NEW! Biomarkers Across Neurodegenerative Diseases
Sponsor: Weston Brain Institute
Description: The Alzheimer’s Association, Alzheimer’s Research UK, The Michael J. Fox Foundation for Parkinson’s Research, and the Weston Brain Institute (Weston) announce a global Request for Applications (RFA) to stimulate analyses across neurodegenerative diseases to increase understanding of pathogenesis similarities and differences. Applicants may request up to two years and $150,000 in total costs. Funding may support but is not limited to: innovative data models, biomarker discovery, assay standardization, genetic profiling, harmonize existing data set phenotypes, analyze cross-disease or longitudinal analyses of existing data, inclusion of other neurodegenerative diseases related to PD and AD including FTLD, or imaging development.
Deadline: Letter of Intent due by September 10, 2018.



NEW! Clinical Research Training Scholarship in ALS
Sponsor: ALS Association and American Brain Foundation
Description: This award aims to encourage young investigators to pursue clinical studies in ALS. The award will consist of a commitment of $65,000 per year for two years, plus a $10,000 per year stipend to support education and research-related costs for a total of $150,000. Supplementation of the award with other grants is permissible, but to be eligible to apply for this award, the other grant source(s) cannot exceed $75,000 annually.
Deadline: Application due by October 1, 2018.



NEW! Richard Olney Clinician Scientist Development Award in ALS
Sponsor: ALS Association, American Brain Foundation
Description: This award aims to encourage young investigators to pursue clinical studies in ALS. A commitment of $75,000 per year for three years, plus a $5,000 per year stipend to support education and research-related costs for a total of $240,000. Supplementation of the award with other grants is permissible, but to be eligible to apply for this award, the other grant source(s) cannot exceed $80,000 annually.
Deadline: Application due by October 1, 2018.



Beckman Young Investigator Awards
Sponsor: Arnold and Mabel Beckman Foundation
Description: The Beckman Young Investigator (BYI) Program provides research support to the most promising young faculty members in the early stages of their academic careers in the chemical and life sciences, particularly to foster the invention of methods, instruments and materials that will open up new avenues of research in science. Grants of up to $600,000 over four years will be awarded. The BYI program is open to those within the first three years of a tenure-track position, or an equivalent independent research appointment, at a United States academic or non-profit institution.
Deadline: Letter of Intent due by August 6, 2018.



Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases
Sponsor: NINDS
Description: The purpose of this funding opportunity announcement (FOA) is to support clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers, or by characterizing cohorts of relevant patients. Through the support of trial readiness studies, NINDS expects to accelerate the initiation of clinical trials for rare diseases and to increase the likelihood of success in those trials. The studies supported through this FOA should be clinical observational studies. No interventional studies will be supported via this funding mechanism.
Deadline: Application due by August 17, 2018.



Beryl Bayley MND Postdoctoral Fellowship
Sponsor: MND Australia
Description: MND Australia’s Postdoctoral Fellowships aim to encourage young researchers to focus their interest on classical forms of MND. Postdoctoral scientists with a track record in areas of neuroscience related to MND and no more than three years postdoctoral research experience. Applicants must be Australian citizens or have permanent resident status. Salary for a full-time research fellow will be funded at $100,000/yr for a period of up to three years.
Deadline: Application due by August 31, 2018.



Betty Laidlaw MND Research Prize
Sponsor: MND Australia
Description: The Betty Laidlaw MND Research Prize aims to reward an outstanding mid-career researcher with a demonstrated background of excellence in neuroscience research. The Prize is for an innovative 12-month project to advance the understanding of classical MND with a clear potential for effective treatments. It aims to support research commencing in the calendar year 2017. The award is a maximum of $250,000 AUS for one year.
Deadline: Application due by August 31, 2018.



Bill Gole MND Postdoctoral Fellowship
Sponsor: MND Australia
Description: MND Australia’s Postdoctoral Fellowships aim to encourage young researchers to focus their interest on classical forms of MND. Postdoctoral scientists with a track record in areas of neuroscience related to MND and no more than three years postdoctoral research experience. Applicants must be Australian citizens or have permanent resident status. Salary for a full-time research fellow will be funded at $100,000/yr for a period of up to three years.
Deadline: Application due by August 31, 2018.



Research Grants
Sponsor: John Templeton Foundation
Description: The Genetics Funding Area seeks to advance genetics research by supporting novel approaches and contrarian projects, especially research that is undervalued by traditional funding sources. In addition to basic and translational research, this Funding Area supports educational programs that increase public awareness concerning the ways in which genetics-related research and its applications advance human well-being at the individual, familial, and societal levels. Awards are given for no more than 3 years. Both grants of at least or at most $234,800 USD are offered depending on the project.
Deadline: Online funding inquiry (OFI) due by August 31, 2018.



Research Grants
Sponsor: MND Australia
Description: These grants provide seed-funding for research that is innovative and has a clear relationship to the causes, treatments or cures of MND or the support of people living with MND. Grants-in-aid support research for one year commencing in the calendar year 2018. The maximum award is up to $100,000 AUS. Applications will begin to be accepted in June.
Deadline: Application due by August 31, 2018.



Sartorius & Science Prize for Regenerative Medicine & Cell Therapy
Sponsor: Science and The Sartorius Group
Description: The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy is an annual prize geared toward researchers focused on basic or translational research that advances regenerative medicine and cell therapy; for example cell-, gene-, or immunotherapy, tissue engineering, and materials engineering. The winner is awarded US$25,000 and publication of his or her essay in Science.
Deadline: Application due by October 1, 2018.



Frick Foundation for ALS Research Award
Sponsor: Bruno and Ilse Frick Foundation for Research on ALS
Description: The aim of the Foundation is to encourage basic biomedical research related to understanding the cause of ALS. The funding is 100,000 CHF over 2 years.
Deadline: Application due by October 8, 2018.



Biomedical Research Project Grants
Sponsor: Motor Neurone Disease Association
Description: The MND Association supports biomedical research on ALS and related conditions, in all relevant disciplines. The objectives of the MND Association research funding programme are to support research aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. Applications will begin to be accepted on September 7, 2018. Researchers outside the UK are eligible to apply if the project is unique in concept or design (i.e. not being performed in the UK) or the project involves a significant collaboration with a UK institute. Applications for project grants should not exceed £85,000 per annum (and £255,000 in total) without the prior agreement of the MND Association.
Deadline: Application due by November 2, 2018.



CLIN 1: Partnering Opportunity for Late Stage Preclinical Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity to accelerate the completion an IND or IDE filing with the FDA and initiate clinical trial start-up with a promising stem or progenitor cell-based treatment that addresses an unmet medical need. The maximum award is $6M USD. CIRM expects projects under this program to advance rapidly into the clinic and to achieve the proposed IND filing within 18 months.
Deadline: Applications due by 2PM PST on the last business day of each month.



CLIN 2: Partnering Opportunity for Clinical Trial Stage Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity to accelerate the completion of a clinical trial for a promising stem or progenitor cell-based treatment that addresses an unmet medical need. The maximum award is $10-15M USD.
Deadline: Applications due by 2PM PST on the last business day of each month.



CLIN 3: Partnering Opportunity for Stem Cell Therapy Registration Clinical Trials
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to support new activities on active CIRM-funded clinical trial projects that will directly enable product registration with the Food and Drug Administration (FDA). This award is only available to holders of a current CLIN2 award for a trial that has been deemed by FDA to be sufficient for registration.
Deadline: Applications due by 2PM PST on the the last business day of each month.



Catalyst Grant: New Genes for Rare Diseases
Sponsor: Rare Diseases Models and Mechanisms Network
Description: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution.
Deadline: Applications will be accepted on a rolling basis.



Clinical Neuroscience Research Grants
Sponsor: Dana Foundation
Description: This grant funds "first-in-man" clinical studies of therapies being developed for brain diseases. Funded studies can receive up to $300,000 payable over three years. Potential applicants may submit a preliminary proposal and budget to determine full proposal eligibility. Applications are not solely restricted to clinical research scientists based in the United States.
Deadline: Applications are accepted on a rolling basis.



DISC 2: The Quest Awards (Stem Cells)
Sponsor: California Institute for Regenerative Medicine (CIRM)
Description: This award program promotes the discovery of promising new stem cell-based technologies that could be translated to enable broad use and ultimately, improve patient care. Projects funded through the Quest Awards should propose technology that is uniquely enabled by human stem/progenitor cells or directly reprogrammed cells, or uniquely enabling for the advancement of stem cell-based therapies. Up to $500,000 USD will be awarded to achieve a candidate that is a diagnostic, a medical device or a tool; or up to $900,000 USD per award to achieve a candidate that is a therapeutic.
Deadline: TBD.



Early Phase Clinical Trials, Canada (Includes FTD)
Sponsor: Weston Brain Institute
Description: The Early Phase Clinical Trials Canada program provides funding to support clinical trials and/or clinical trial sub-studies that could accelerate the development of therapeutics for neurodegenerative disease aging, including FTD. Eligible principal investigators must be at or above the level of Assistant Professor or equivalent, and be affiliated with a CRA-qualified institution located in Canada. A maximum of $1,500,000 per project over up to 4 years.
Deadline: Applications will be accepted on a rolling basis.



NIH Scored Unfunded Grants (includes FTD)
Sponsor: Alzheimer's Drug Discovery Foundation
Description: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.
Deadline: Applications are accepted on a rolling basis.



NIH TRND Program and NIH BrIDGs Program
Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Now accepting rolling applications.



NINDS Training and Career Development Awards
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.



NeuroNEXT Infrastructure Resource Access
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description:

This funding opportunity announcement (FOA) encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.


Deadline: Applications are accepted on a rolling basis.



Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail